MGA1012 (and other DART): This is 3X to 5X Opd/Key dose/regime! What the facxx they are thinking?
Actually, phase 1 pembro dose went that high. Compare for yourself:
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients With Advanced Solid Tumors
A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors
They are spending $~45M on R&D + G&A, so by now they should show some "meat" not only "bones"!
A large chunk of the R&D spend goes to the P3 program for a drug that I don't think any of us have high hopes for, so I agree with you there. You seemed more constructive on this a few months ago, and things are progressing at the expected pace since then, so what's changed for you?